Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

Summary

This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription medications. Genes, which are inherited from parents, carry information that determines things such as eye color and blood type. Genes can also influence how patients process and respond to medications. Depending on the genetic makeup, some medications may work faster or slower or produce more or fewer side effects. Pharmacogenomics testing may help doctors learn more about how patients break down and process specific medications based on their genes and improve the quality of life of cancer patients receiving clinical care.

Conditions

• Anatomic Stage III Breast Cancer AJCC v8
• Anatomic Stage IIIA Breast Cancer AJCC v8
• Anatomic Stage IIIB Breast Cancer AJCC v8
• Anatomic Stage IIIC Breast Cancer AJCC v8
• Anatomic Stage IV Breast Cancer AJCC v8
• Biliary Tract Carcinoma
• Clinical Stage III Cutaneous Melanoma AJCC v8
• Clinical Stage IV Cutaneous Melanoma AJCC v8
• Malignant Brain Neoplasm
• Malignant Genitourinary System Neoplasm
• Malignant Solid Neoplasm
• Pancreatobiliary Carcinoma
• Pathologic Stage III Cutaneous Melanoma AJCC v8
• Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
• Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
• Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
• Pathologic Stage IV Cutaneous Melanoma AJCC v8
• Prognostic Stage III Breast Cancer AJCC v8
• Prognostic Stage IIIA Breast Cancer AJCC v8
• Prognostic Stage IIIB Breast Cancer AJCC v8
• Prognostic Stage IIIC Breast Cancer AJCC v8
• Prognostic Stage IV Breast Cancer AJCC v8
• Stage III Colorectal Cancer AJCC v8
• Stage III Ovarian Cancer AJCC v8
• Stage III Pancreatic Cancer AJCC v8
• Stage III Prostate Cancer AJCC v8
• Stage IIIA Colorectal Cancer AJCC v8
• Stage IIIA Ovarian Cancer AJCC v8
• Stage IIIA Prostate Cancer AJCC v8
• Stage IIIB Colorectal Cancer AJCC v8
• Stage IIIB Ovarian Cancer AJCC v8
• Stage IIIB Prostate Cancer AJCC v8
• Stage IIIC Colorectal Cancer AJCC v8
• Stage IIIC Ovarian Cancer AJCC v8
• Stage IIIC Prostate Cancer AJCC v8
• Stage IV Colorectal Cancer AJCC v8
• Stage IV Ovarian Cancer AJCC v8
• Stage IV Pancreatic Cancer AJCC v8
• Stage IV Prostate Cancer AJCC v8
• Stage IVA Colorectal Cancer AJCC v8
• Stage IVA Ovarian Cancer AJCC v8
• Stage IVA Pancreatic Cancer
• Stage IVA Prostate Cancer AJCC v8
• Stage IVB Colorectal Cancer AJCC v8
• Stage IVB Ovarian Cancer AJCC v8
• Stage IVB Pancreatic Cancer
• Stage IVB Prostate Cancer AJCC v8
• Stage IVC Colorectal Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of saliva

OTHER

Genetic Testing

Undergo pharmacogenomics testing

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Jewel Samadder, M.D. · Mayo Clinic

Study Design

Allocation

NA

Purpose

SCREENING

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2019-06-06

Primary Completion

2022-10-06

Completion

2022-10-06

Countries

• United States

Study Locations